NCT04447898View on ClinicalTrials.gov

Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Knee Osteoarthritis
Interventions
DRUG

PPV-06 10 μg

Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

DRUG

PPV-06 50 μg

High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

DRUG

Placebo

Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112

Trial Locations (1)

Unknown

Cic Cochin, Paris

Sponsors

Lead Sponsor

Peptinov SAS
All Listed Sponsors
lead

Peptinov SAS

INDUSTRY